Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report - Top-Institutions - MDSpire

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • By

  • Fu-Yi Wang

  • Li-Long Zhu

  • Cheng Ji

  • Jie Deng

  • Lu Han

  • Fei Song

  • Zhong Chen

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Hepatology

  • #2

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #3

    The University of California Los Angeles
    The University of California Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • by Fu-Yi Wang, Li-Long Zhu, Cheng Ji, Jie Deng, Lu Han, Fei Song, Zhong Chen

  • June 2, 2026

Related Content

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

Bibliometric analysis of exercise and cancer prognosis research: trends, thematic evolution, and global collaborations (2015–2024)

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer